Address:
2-4-16, Kyobashi, Chuo-ku, Tokyo 104-8002, Japan.
Phone Number:
+81-3-3273-6030
Fax Number:
+81-3-3281-7046
Company Contact Email:
https://www.meiji.com/global/contact-us/
Website:
https://www.meiji.com/global/pharmaceuticals/
Employees:
5,683 employees (including consolidated group companies) as of March 31, 2025.
Capital:
28,363 million yen.
Revenue:
Net sales (consolidated total of Meiji Holdings' Pharmaceutical Segment) for FY2024: 229,650 million yen.
Main Clients:
Major domestic pharmaceutical distributors; leading international pharmaceutical companies (for CMO/CDMO services).
Introduction of your company & business:
Meiji Seika Pharma is dedicated to advancing pharmacological treatments by developing brand-name drugs and providing high-quality generics. The company focuses on infectious diseases and aims to contribute to global health through innovative pharmaceutical solutions, manufacturing excellence, and a commitment to healthcare and wellness.
Mission/Vision:
To embody good ideas that promote wellness and health worldwide, contributing to a brighter, healthier future with innovation and a focus on infectious disease control.
History:
1916: Tokyo Confectionery Co., Ltd. (later known as Meiji Seika) established.
1946: Started the pharmaceutical business with penicillin production during a nationwide shortage.
1974: P.T. Meiji Indonesian Pharmaceutical Industries established.
1989: The antianxiety drug MEILAX launched.
1999: Launch of DEPROMEL, Japan's first SSRI antidepressant.
2011: Meiji Seika Pharma Co., Ltd. succeeded the pharmaceutical business of Meiji Seika following a reorganization of the Meiji Group.
2015: Medreich Ltd. (India) joined the Group, serving in CMO/CDMO business.
2016: Me Pharma was established as a subsidiary manufacturing and selling generic drugs.
2018: KM Biologics Co., Ltd. joined the Group, focusing on research, development, and manufacturing of biological drugs.
2024: Launch of KOSTAIVE, a self-amplifying mRNA vaccine against COVID-19, along with QUINTOVAC (five-in-one vaccine) and REZUROCK (ROCK2 inhibitor).
Key Products or Services:
Pharmaceutical drugs for infectious diseases, including vaccines, antibacterial drugs, and generic medicines, as well as contract manufacturing services.
Technology / R&D activities:
Meiji Seika Pharma is committed to safeguarding lives through the development of new drugs and vaccines. The company's strengths in R&D also encompass generic medicines. With multiple research centers and laboratories, it focuses on creating innovative solutions for urgent health issues around the world.
International Operations:
Global presence with subsidiaries and production facilities in Indonesia, Thailand, China, Spain, and India, supporting international demand for pharmaceutical manufacturing.
Business Achievements:
Since successfully exporting antibacterial drugs globally in the 1950s, the company began expanding into Southeast Asia by establishing subsidiaries in the 1970s. It also entered the vaccine business through the products manufactured by KM Biologics and integrated Medreich Ltd. in India to support extensive contract manufacturing.
Company Goals & Objectives:
Meiji Seika Pharma aims to expand sales of infectious disease products, generic medicines, and biopharmaceuticals both in Japan and overseas. The company will focus on strengthening production, R&D, and marketing to position itself as the leading pharmaceutical company in Asia for infectious diseases. The goal is to achieve a 9% CAGR in operating income and over 30% of sales from overseas for Meiji Holdings' Pharmaceutical Segment by FY2026.
